RxDoctor Payments Data

Andrew Rosenfeld, DO

Hospitalist · Saint Paul, VANPI 1740772359

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 31.9% of the total. 2024 is the largest year on record at $256, 8.3 times the $31 reported in 2020.

$535in general payments, 2019–2025

Across 29 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$171
  • AbbVie$99
  • Johnson & Johnson$67
  • Axsome Therapeutics, Inc.$36
  • Novo Nordisk$31
  • E.r. Squibb & Sons, L.L.C.$27
  • plus $105 from 6 others

What the payments were for

  • Food & beverage$535100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$535 in reported general payments places this provider in the 85th percentile of 539 hospitalist providers in Virginia.

See all hospitalist providers in Virginia

Medicare billing

Part B allowed, 2024
$16,022
Medicare patients
89
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole15$24,805
VraylarCariprazine Hcl12$18,337
TrintellixVortioxetine Hydrobromide13$10,715
Aripiprazole22$737
Bupropion XlBupropion Hcl18$694
Lamotrigine31$559
Propranolol Hcl49$454
Duloxetine Hcl23$402
Cefdinir26$395
Clonazepam37$331
Sertraline Hcl30$327
Buspirone Hcl16$319
Amitriptyline Hcl11$269
Mirtazapine12$238
Trazodone Hcl33$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$99$18,33712 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$19$10,71513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 539 hospitalist providers in Virginia.

Other hospitalist in Saint Paul

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →